Nonglycemic effects of incretins in patients with long-term type 1 diabetes mellitus and chronic kidney disease


Cite item

Full Text

Abstract

Aim. To investigate the nonglycemic effects of incretins in patients with type 1 diabetes mellitus (DM1) of long duration (for more than 20 years) and chronic kidney disease. Subjects and methods. Seventy-five patients with varying degrees of diabetic nephropathy (DN) and without this condition, including patients receiving renal replacement therapy with programmed hemodialysis and those who had undergone kidney transplantation were examined. The levels of phosphorus-calcium metabolic indicators (calcium, phosphorus, parathyroid hormone, vitamin D, and fibroblast growth factor 23 (FGF-23)), the cardiac damage marker atrial natriuretic peptide, the proinflammatory markers monocyte chemoattractant protein 1 (MCP-1) and C-reactive protein (CRP) and the fibrotic marker transforming growth factor-β, as well as those of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) were estimated in addition to conventional examination methods. All the patients underwent cardiac multislice spiral computed tomography, by calculating the Agatston index (calcium index (CI)) reflecting the degree of coronary artery calcification. Results. The investigation revealed no relationship of GLP-1 and GIP levels to the presence and degree of DN in the patients of the study groups. GLP-1 was noted to be inversely related to patient age, indicating the diminished secretion of this peptide in older people. There was evidence that GLP-1 positively affected blood lipid composition (total cholesterol: r=–0,320; p<0.05) and the magnitude of coronary artery calcification (CI: r=–0.308; p<0.05). GIP showed a differently directed effect on the proinflammatory factors: fibrinogen (r=–0.264; p<0.05), CRP (r=–0.626; p<0.05), and FGF-23 (r=–0.341; p<0.05). Conclusion. The investigation has demonstrated the nonglycemic effects of incretins that favorably affect the pathogenetic processes underlying the late complications of DM1. The findings point to the potential efficacy of incretin-based drugs in preventing and treating the late complications of DM, which necessitates the conduction of larger investigations.

References

  1. Jens J. Hoist The physiology and pharmacology of incretins in type 2 diabetes mellitus Journal Compilation 2008 Blackwell Publishing Ltd. Diabet, Obes Metabol. 2008;10(Suppl. 3):14-21.
  2. Дедов И.И., Шестакова М.В., Сухарева О.Ю. Инновации в лечении сахарного диабета 2 типа: применение инкретинов. Терапевтический архив. 2010;10:5-10.
  3. Бова Е.В., Пакус Е.Н. Использование инкретиномиметиков в лечении больных сахарным диабетом 2 типа. Фундаментальные исследования. 2009;10:6-9.
  4. Stonehouse AH, Darsow T, Maggs DG. Incretin-based therapies. J Diabetes. 2012;4(1):55-67.
  5. Сухарева О.Ю., Шмушкович И.А., Шестакова Е.А., Шестакова М.В. Система инкретинов при сахарном диабете 2-го типа: сердечно-сосудистые эффекты. Проблемы эндокринологии. 2012;6:33-42.
  6. Panchapakesan U, Mather A, Pollock C. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Scie. 2013;124:17-26.
  7. Siemianowicz K, Francuz T, Garczorz W The influence of exendin and GLP-1 on VCAM-1 and ICAM-1 production in endothelium stimulated by TNF-α and glycated albumin. Health. 2012;4(12А):1570-1577.
  8. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, Rittig S, Christiansen JS. Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab. 2013;98(4):664-671. doi: 10.1210/jc.2012-3855.
  9. Gutzwiller JP, Hruz P, Huber AR, Hamel C, Zehnder C, Drewe J, Gutmann H, Stanga Z, Vogel D, Beglinger C Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73(2-3):142-150.
  10. Vallon V, Docherty NG. Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4. Exp Physiol. 2014;99(9):1140-1145. doi: 10.1113/expphysiol.2014.078766.
  11. Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, M. Frey D, Keller U, Müller B, Christ-Crain M. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol Endocrinol Metab. 2013;304(1):1-13. doi: 10.1152/ajpendo.00100.2012.
  12. Harrison LB, Mora PF, Clark GO, Lingvay I. Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs. J Investig Med. 2013;61(1):40-44. doi:10.231/jim.0b013e318279b7d6.
  13. Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T, Holst JJ, Madsbad S, Andersen HU. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes — a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open. 2015;5(4):e007791. doi: 10.1136/bmjopen-2015-007791.
  14. Шестакова Е.А., Ильин А.В., Шестакова М.В., Дедов И.И. Секреция гормонов инкретинового ряда у лиц с факторами риска развития сахарного диабета 2-го типа. Терапевтический архив. 2014(10):10-14.
  15. Plutzky J. The Incretin Axis in Cardiovascular Disease. Circulation. 2011;124:2285-2289. doi: 10.1161/circulationaha.111.06413.
  16. Ravassa S, Zudaire A, Diez J. GLP-1 and cardioprotection. From bench to bedside. Cardiovasc Res. 2012;94:316-332.
  17. Gomez N, Touihri K, Matheeussen V. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur JHeart Fail. 2012;14(1):14-22.
  18. Fields AV, Patterson B, Karnik AA, Shannon RP. Glucagon-like peptide-1 and myocardial protection: more than glycemic control. Clin Cardiol. 2009;32:236-243.
  19. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
  20. Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001;26:245-251.
  21. London GM, Guerin AP, Marchais S. Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-1740.
  22. Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, Demoss D, Nuguri V, Nabavi V, Ratakonda R, Berman DS, Raggi P. Progression of coronary artery calcium predicts all-cause mortality. JACC CardiovascImag. 2010;3(12):1229-1236.
  23. Jun-Kun Zhan, Pan Tan, Yan-Jiao Wang, Yi Wang, Jie-Yu He, Zhi-Yong Tang, Wu Huang, and You-Shuo Liu Exenatide can inhibit calcification of human VSMCs through the NF-kappa B/RANKL signaling pathway. CardiovascDiabetol. 2014;13:153-160. doi: 10.1186/s12933-014-0153-4.
  24. Changting Xiao, Satya Dash, Gary F. Lewis Mechanisms of Incretin Effects on Plasma Lipids and Implications for the Cardiovascular System. Cardiovasc Hematol Agents Med Chem. 2012;10:289-294.
  25. Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfun ction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol. 2011;10:61-68.
  26. Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я., Клефортова И.И., Сухарева О.Ю., Викулова О.К., Зайцева Н.В., Мартынов С.А., Кварацхелия М.В., Тарасов Е.В., Трубицына Н.П. Сахарный диабет и хроническая болезнь почек: достижения, нерешенные проблемы и перспективы лечения. Сахарный диабет. 2011;1:81-88.
  27. Allen KV, Walker JD. Microalbuminuria and mortality in long-duration type 1 diabetes. Diabetes Care. 2003;26(8):2389-2391.
  28. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-128.
  29. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets. 2007;8:952-959.
  30. Schlatter P, Beglinger C, Drewe J, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141:120-128.
  31. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem. 2002;277:20309-203015.
  32. Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism. 2011;60:1271-1277.
  33. Tanaka T, HigashijimaY, Wada T, Nangaku M. The potential for renoprotection with incretin-based drugs. Kidney Intern. 2014;86:701-711.
  34. Kodera R, Shikata K, Kataoka HU. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia. 2011;54:965-978.
  35. Li W, Cui M, Wei Y. Inhibition of the expression of TGF-b1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. CellPhysiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2012;30:749-757.
  36. Skov J. Effects of GLP-1 in the kidney. Rev Endocr Metab Disord. 2014;15(3):197-207. doi: 10.1007/s11154-014-9287-7.
  37. Jensen EP. Activation of renal GLP-1 receptors located in the afferent arteriole causes an increase in renal blood flow. Diabetologia. 2013;56:255-263.
  38. Nie Y, Ma RC, Chan JC, Xu H, Xu G. Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes. FASEB J. 2012;26:2383-2393.
  39. Timper K, Grisouard J, Sauter NS, Herzog-Radimerski T, Dembinski K, Peterli R, Frey DM, Zulewski H, Keller U, Müller B, Christ-Crain M. Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes. Am J Physiol — Endocrin Metabol. 2013;304(1):1-13. doi: 10.1152/ajpendo.00100.2012.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies